Sarepta says teen died after its gene therapy treatment
By Sriparna Roy and Bhanvi Satija (Reuters) – Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company’s U.S-approved gene therapy for a rare muscular dystrophy. The patient underwent treatment in December with Sarepta’s therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys …
Sarepta says teen died after its gene therapy treatment Read More »









